1 |
Gatto L, Franceschi E, Tosoni A, Di Nunno V, Bartolini S, Brandes AA. Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022. Expert Opin Drug Discov 2023;18:269-86. [PMID: 36718723 DOI: 10.1080/17460441.2023.2174097] [Reference Citation Analysis]
|
2 |
Ye Y, Zhong W, Qian J, Zhang J, Xu T, Han R, Han J, Wang C, Song L, Zeng X, Wang H. Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme. Front Cell Dev Biol 2023;11:1042490. [PMID: 36711038 DOI: 10.3389/fcell.2023.1042490] [Reference Citation Analysis]
|
3 |
Schatz J, Ladinig A, Fietkau R, Putz F, Gaipl US, Frey B, Derer A. Normofractionated irradiation and not temozolomide modulates the immunogenic and oncogenic phenotype of human glioblastoma cell lines. Strahlenther Onkol 2022. [DOI: 10.1007/s00066-022-02028-8] [Reference Citation Analysis]
|
4 |
Zhou J, Li L, Jia M, Liao Q, Peng G, Luo G, Zhou Y. Dendritic cell vaccines improve the glioma microenvironment: Influence, challenges, and future directions. Cancer Medicine 2022. [DOI: 10.1002/cam4.5511] [Reference Citation Analysis]
|
5 |
Drakulic D, Schwirtlich M, Petrovic I, Mojsin M, Milivojevic M, Kovacevic-grujicic N, Stevanovic M. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma. Cells 2022;11:2530. [DOI: 10.3390/cells11162530] [Reference Citation Analysis]
|
6 |
Wu Y, Peng Z, Wang H, Xiang W. Identifying the Hub Genes of Glioma Peritumoral Brain Edema Using Bioinformatical Methods. Brain Sci 2022;12:805. [PMID: 35741689 DOI: 10.3390/brainsci12060805] [Reference Citation Analysis]
|